Overview
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.
Eligibility
Inclusion Criteria:
- Failed 2 or more lines of chemotherapy
- Tumor overexpressing either MET or EGFR
- Measurable lesion
Exclusion Criteria:
- Prior treatment with anti-MET/EGFR bispecific antibody